3-allylpiperidine | 1260880-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-allylpiperidine
• 英文别名: 3-(Prop-2-en-1-yl)piperidine；3-prop-2-enylpiperidine
• CAS: 1260880-04-3
• 化学式: C₈H₁₅N
• 分子量: 125.214
• InChiKey: DOVPSHLIYFKBPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-allylpiperidine 在 sodium carbonate 、 mesylate[(di(1-adamantyl)-n-butylphosphine)-2-(2’-amino-1,1’-biphenyl)]palladium(II) 、 lithium hexamethyldisilazane 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 34.17h， 生成 4-(3-allylpiperidin-1-yl)-7-(3-chloro-2-(hex-5-en-1-yl)-5-(methoxymethoxy)phenyl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidine
  参考文献：
  名称：

  PYRIDOPYRIMIDINE KRAS INHIBITORS

  摘要：

  This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a), (I-aa), (I-b), (I-bb), (I-c), (I-cc), (I-d), (I-dd), (I-e), (I-ee), (I-f), (I-g), or (I-h)), Formula (II) (e.g., (II-c), (II-cc), (II-d), (II-dd), (II-e), (II-ee), (II-f), (II-g), or (II-h)), or Formula (Aa)), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. In some embodiments, the KRas protein has a dysregulation (e.g., the KRas protein is mutated or amplified). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and/or sustained (e.g., excessive) KRas activation, for example, KRas activation associated with a mutant KRas protein, contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

  公开号：

  WO2024040131A1
• 作为产物：
  描述：

  3-Allyl-piperidine-1-carboxylic acid tert-butyl ester 生成 3-allylpiperidine
  参考文献：
  名称：

  Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

  摘要：

  式I的化合物： 其中A、B、D、L、R1、R2、R3、R4、m和n的定义如描述中所定义。本发明还涉及制备这些化合物的方法，以及用于制备的新中间体，含有这些化合物的药物组合物，以及这些化合物在治疗中的应用。

  公开号：

  US20090192169A1

文献信息

• New carboxylic acid amides, the preparation thereof and their use as medicaments
  申请人：Priepke Henning

  公开号：US20050203078A1

  公开（公告）日：2005-09-15

  The present invention relates to new substituted carboxylic acid amides of general formula wherein A, B and R 1 to R 5 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式的新取代羧酸酰胺 其中A、B和R1至R5如权利要求1中定义，其互变异构体、对映体、非对映异构体、它们的混合物及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的性质。
• SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS
  申请人：Dahmann Georg

  公开号：US20080051578A1

  公开（公告）日：2008-02-28

  The present invention relates to compounds of general formula (I) wherein A, B, L, R 1 , R 2 , R 3a and R 3b are defined as in the specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式(I)的化合物，其中A、B、L、R1、R2、R3a和R3b如规范中定义，其互变异构体、对映体、非对映体、其混合物及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的性质。
• NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS
  申请人：Gerlach Kai

  公开号：US20060142263A1

  公开（公告）日：2006-06-29

  The present invention relates to new substituted pyrrolidinones of general formula wherein A, X, B and R 1 to R 9 are as defined above, or a tautomer or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式为的新取代吡咯烷酮，其中A、X、B和R1到R9如上定义，或其互变异构体或盐，特别是其与无机或有机酸或碱的生理上可接受的盐，具有有价值的性质。
• SUBSTITUTED GLYCINAMIDES, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS
  申请人：Priepke Henning

  公开号：US20100216769A1

  公开（公告）日：2010-08-26

  The present invention relates to new substituted glycinamides of general formula (I) wherein D, M, R 3 , R 4 and R 5 are defined as in the specification, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般式(I)的新取代甘氨酰胺，其中D、M、R3、R4和R5如规范中定义，其互变异构体、对映异构体、非对映异构体、混合物以及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的特性。
• New substituted thiophene carboxamides, process for their preparation and their use as medicaments
  申请人：Pfau Roland

  公开号：US20050256107A1

  公开（公告）日：2005-11-17

  The present invention relates to new substituted thiophene-2-carboxylic acid amides of general formula wherein A, and R 1 to R 8c are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties.

  本发明涉及一般公式中的新取代噻吩-2-羧酸酰胺，其中A和R1至R8如权利要求书中定义，其酮式、对映体、非对映体、其混合物及其盐，特别是其与无机或有机酸或碱形成的生理上可接受的盐，具有有价值的性质。